Differential immune responses to staphylococcal enterotoxin B mutations in a hydrophobic loop dominating the interface with major histocompatibility complex class II receptors

The Journal of Infectious Diseases
M A WoodyBradley G Stiles

Abstract

Bacterial superantigens, such as staphylococcal enterotoxin B (SEB), can trigger acute pathologic effects in humans. A hydrophobic loop on the surface of SEB and other bacterial superantigens, centered around a conserved leucine (L45) residue, is essential for binding to class II major histocompatibility complex molecules. Single residue changes of wild type SEB, designated Q43P, F44P, or L45R, resulted in nonlethal proteins at a dose equivalent to 30 murine LD50 of SEB. Relative to SEB, the mutant proteins did not elevate serum concentrations of proinflammatory cytokines in mice and caused minimal proliferation of human lymphocytes. Anti-SEB titers of mice immunized with Q43P, F44P, L45R, or SEB were similar and protected 77%-100% of animals against a lethal SEB challenge. Levels of toxin-specific IgG1, IgG2a, IgG2b, and IgG3 in mice immunized with SEB, Q43P, or F44P were equivalent, but animals immunized with L45R had significantly elevated levels of IgG2a and IgG2b. Vaccines against staphylococcal superantigens should focus on this critical leucine residue.

Citations

Dec 2, 1999·Immunologic Research·T Krakauer
Jul 17, 2003·Clinical Immunology : the Official Journal of the Clinical Immunology Society·James W BolesSina Bavari
Jun 12, 2012·Analytical Chemistry·George P AndersonEllen R Goldman
May 14, 2014·BioMed Research International·Laura C HudsonKenneth J Piller
Sep 17, 2008·Research in Veterinary Science·Louis M HuzellaTeresa Krakauer
Jun 7, 2005·Advanced Drug Delivery Reviews·Nicholas J Mantis
Aug 21, 2013·Virulence·Teresa Krakauer, Bradley G Stiles
Feb 24, 2000·Journal of Periodontal Research·E Josefsson, A Tarkowski
Jul 3, 1999·Clinical and Diagnostic Laboratory Immunology·T Krakauer, B G Stiles

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.